USFDA accepts Bristol Myers Squibb sBLA for Opdivo for Resected Stage IIB/C Melanoma Ruchika Sharma4 March 2023 10:00 AM ISTMelanoma is a form of skin cancer characterized by the uncontrolled growth of pigment-producing cells (melanocytes) located in the skin.
Medical Bulletin 13/September/2022 Isra Zaman13 Sept 2022 12:07 PM ISTHere are the top medical news for the day:Immunotherapy before surgery helpful for common skin cancer patients: StudyIn an international, multicenter...
Novel combination immunotherapy for patients with metastatic colorectal cancer Isra Zaman13 Sept 2022 9:45 AM ISTA physician-scientist at City of Hope, has identified a novel combination immunotherapy regimen that demonstrated significant response in a subgroup...
Nivolumab combo with chemotherapy or ipilimumab prolongs survival in Advanced esophageal carcinoma Dr. Kamal Kant Kohli8 Aug 2022 8:00 PM ISTNivolumab has recently been approved both in combination with fluoropyrimidine-and platinum-based combination chemotherapy and in combination with...
Setback: Bristol Myers drug combo fails to meet main goal in kidney cancer trial Ruchika Sharma30 July 2022 1:15 PM ISTRenal cell carcinoma (RCC) is the most common type of kidney cancer in adults
Bristol Myers Opdivo fails to meet primary endpoint in CheckMate -901 trial Ruchika Sharma19 May 2022 10:15 AM ISTUrothelial carcinoma, which most frequently begins in the cells that line the inside of the bladder, accounts for approximately 90% of bladder cancer...
Bristol Myers Squibb, Nektar halt Bempegaldesleukin, Opdivo cocktail trials for cancer treatment Ruchika Sharma16 April 2022 2:57 PM ISTPrinceton: Nektar Therapeutics and Bristol Myers Squibb have announced that based on results from pre-planned analyses of two...
Bristol Myers sues AstraZeneca over cancer-treatment patents MD Bureau19 March 2022 6:08 PM ISTBristol asked the Delaware court for an undisclosed amount of monetary damages.
Bristol Myers Squibb Nivolumab marketing approval to be revoked for hepatocellular carcinoma: CDSCO panel Dr. Divya Colin14 March 2022 6:30 PM ISTNew Delhi: In a major setback for Bristol Myers Squibb, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO)...
Nivolumab and Ipilimumab combo bests monotherapy in improving clinical outcomes in Advanced Melanoma MD Editorial Team17 Dec 2021 9:00 AM ISTIn a new study CheckMate 067, the results demonstrated durable, improved clinical outcomes with nivolumab plus ipilimumab or nivolumab versus...
Nivolumab + ipilimumab: Added benefit in pleural mesothelioma with non-epithelioid tumour histology Hina Zahid12 Oct 2021 9:00 AM ISTThe monoclonal antibodies nivolumab and ipilimumab have already undergone several early benefit assessments in various oncological indications. Since...
Following Checkmate-274 trial, FDA approves adjuvant Nivolumab for high-risk Urothelial Carcinoma Dr Nisanth Puliyath25 Aug 2021 9:00 AM ISTUrothelial carcinoma (UC), is the most common type of bladder cancer in adults. In addition to the bladder, UC can occur in other parts of the urinary...
